Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo

Wendy Noble, Emmanuel Planel, Cindy Zehr, Vicki Olm, Jordana Meyerson, Farhana Suleman, Kate Gaynor, Lili Wang, John LaFrancois, Boris Feinstein, Mark Burns, Pavan Krishnamurthy, Yi Wen, Ratan Bhat, Jada Lewis, Dennis W Dickson, Karen Duff

Research output: Contribution to journalArticle

524 Citations (Scopus)

Abstract

Neurofibrillary tangles composed of hyperphosphorylated, aggregated tau are a common pathological feature of tauopathies, including Alzheimer's disease. Abnormal phosphorylation of tau by kinases or phosphatases has been proposed as a pathogenic mechanism in tangle formation. To investigate whether kinase inhibition can reduce tauopathy and the degeneration associated with it in vivo, transgenic mice overexpressing mutant human tau were treated with the glycogen synthase kinase-3 (GSK-3) inhibitor lithium chloride. Treatment resulted in significant inhibition of GSK-3 activity. Lithium administration also resulted in significantly lower levels of phosphorylation at several epitopes of tau known to be hyperphosphorylated in Alzheimer's disease and significantly reduced levels of aggregated, insoluble tau. Administration of a second GSK-3 inhibitor also correlated with reduced insoluble tau levels, supporting the idea that lithium exerts its effect through GSK-3 inhibition. Levels of aggregated tau correlated strongly with degree of axonal degeneration, and lithium-chloride- treated mice showed less degeneration if administration was started during early stages of tangle development. These results support the idea that kinases are involved in tauopathy progression and that kinase inhibitors may be effective therapeutically.

Original languageEnglish (US)
Pages (from-to)6990-6995
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume102
Issue number19
DOIs
StatePublished - May 10 2005

Fingerprint

Tauopathies
Glycogen Synthase Kinase 3
Lithium
Phosphotransferases
Lithium Chloride
Alzheimer Disease
Phosphorylation
Neurofibrillary Tangles
Phosphoric Monoester Hydrolases
Transgenic Mice
Epitopes
Inhibition (Psychology)

Keywords

  • Alzheimer's disease
  • Neurofibrillary tangles
  • Phosphorylation
  • Tau protein

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. / Noble, Wendy; Planel, Emmanuel; Zehr, Cindy; Olm, Vicki; Meyerson, Jordana; Suleman, Farhana; Gaynor, Kate; Wang, Lili; LaFrancois, John; Feinstein, Boris; Burns, Mark; Krishnamurthy, Pavan; Wen, Yi; Bhat, Ratan; Lewis, Jada; Dickson, Dennis W; Duff, Karen.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 19, 10.05.2005, p. 6990-6995.

Research output: Contribution to journalArticle

Noble, W, Planel, E, Zehr, C, Olm, V, Meyerson, J, Suleman, F, Gaynor, K, Wang, L, LaFrancois, J, Feinstein, B, Burns, M, Krishnamurthy, P, Wen, Y, Bhat, R, Lewis, J, Dickson, DW & Duff, K 2005, 'Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo', Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 19, pp. 6990-6995. https://doi.org/10.1073/pnas.0500466102
Noble, Wendy ; Planel, Emmanuel ; Zehr, Cindy ; Olm, Vicki ; Meyerson, Jordana ; Suleman, Farhana ; Gaynor, Kate ; Wang, Lili ; LaFrancois, John ; Feinstein, Boris ; Burns, Mark ; Krishnamurthy, Pavan ; Wen, Yi ; Bhat, Ratan ; Lewis, Jada ; Dickson, Dennis W ; Duff, Karen. / Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. In: Proceedings of the National Academy of Sciences of the United States of America. 2005 ; Vol. 102, No. 19. pp. 6990-6995.
@article{6dd1498936dd43bd957514ce601028ba,
title = "Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo",
abstract = "Neurofibrillary tangles composed of hyperphosphorylated, aggregated tau are a common pathological feature of tauopathies, including Alzheimer's disease. Abnormal phosphorylation of tau by kinases or phosphatases has been proposed as a pathogenic mechanism in tangle formation. To investigate whether kinase inhibition can reduce tauopathy and the degeneration associated with it in vivo, transgenic mice overexpressing mutant human tau were treated with the glycogen synthase kinase-3 (GSK-3) inhibitor lithium chloride. Treatment resulted in significant inhibition of GSK-3 activity. Lithium administration also resulted in significantly lower levels of phosphorylation at several epitopes of tau known to be hyperphosphorylated in Alzheimer's disease and significantly reduced levels of aggregated, insoluble tau. Administration of a second GSK-3 inhibitor also correlated with reduced insoluble tau levels, supporting the idea that lithium exerts its effect through GSK-3 inhibition. Levels of aggregated tau correlated strongly with degree of axonal degeneration, and lithium-chloride- treated mice showed less degeneration if administration was started during early stages of tangle development. These results support the idea that kinases are involved in tauopathy progression and that kinase inhibitors may be effective therapeutically.",
keywords = "Alzheimer's disease, Neurofibrillary tangles, Phosphorylation, Tau protein",
author = "Wendy Noble and Emmanuel Planel and Cindy Zehr and Vicki Olm and Jordana Meyerson and Farhana Suleman and Kate Gaynor and Lili Wang and John LaFrancois and Boris Feinstein and Mark Burns and Pavan Krishnamurthy and Yi Wen and Ratan Bhat and Jada Lewis and Dickson, {Dennis W} and Karen Duff",
year = "2005",
month = "5",
day = "10",
doi = "10.1073/pnas.0500466102",
language = "English (US)",
volume = "102",
pages = "6990--6995",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "19",

}

TY - JOUR

T1 - Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo

AU - Noble, Wendy

AU - Planel, Emmanuel

AU - Zehr, Cindy

AU - Olm, Vicki

AU - Meyerson, Jordana

AU - Suleman, Farhana

AU - Gaynor, Kate

AU - Wang, Lili

AU - LaFrancois, John

AU - Feinstein, Boris

AU - Burns, Mark

AU - Krishnamurthy, Pavan

AU - Wen, Yi

AU - Bhat, Ratan

AU - Lewis, Jada

AU - Dickson, Dennis W

AU - Duff, Karen

PY - 2005/5/10

Y1 - 2005/5/10

N2 - Neurofibrillary tangles composed of hyperphosphorylated, aggregated tau are a common pathological feature of tauopathies, including Alzheimer's disease. Abnormal phosphorylation of tau by kinases or phosphatases has been proposed as a pathogenic mechanism in tangle formation. To investigate whether kinase inhibition can reduce tauopathy and the degeneration associated with it in vivo, transgenic mice overexpressing mutant human tau were treated with the glycogen synthase kinase-3 (GSK-3) inhibitor lithium chloride. Treatment resulted in significant inhibition of GSK-3 activity. Lithium administration also resulted in significantly lower levels of phosphorylation at several epitopes of tau known to be hyperphosphorylated in Alzheimer's disease and significantly reduced levels of aggregated, insoluble tau. Administration of a second GSK-3 inhibitor also correlated with reduced insoluble tau levels, supporting the idea that lithium exerts its effect through GSK-3 inhibition. Levels of aggregated tau correlated strongly with degree of axonal degeneration, and lithium-chloride- treated mice showed less degeneration if administration was started during early stages of tangle development. These results support the idea that kinases are involved in tauopathy progression and that kinase inhibitors may be effective therapeutically.

AB - Neurofibrillary tangles composed of hyperphosphorylated, aggregated tau are a common pathological feature of tauopathies, including Alzheimer's disease. Abnormal phosphorylation of tau by kinases or phosphatases has been proposed as a pathogenic mechanism in tangle formation. To investigate whether kinase inhibition can reduce tauopathy and the degeneration associated with it in vivo, transgenic mice overexpressing mutant human tau were treated with the glycogen synthase kinase-3 (GSK-3) inhibitor lithium chloride. Treatment resulted in significant inhibition of GSK-3 activity. Lithium administration also resulted in significantly lower levels of phosphorylation at several epitopes of tau known to be hyperphosphorylated in Alzheimer's disease and significantly reduced levels of aggregated, insoluble tau. Administration of a second GSK-3 inhibitor also correlated with reduced insoluble tau levels, supporting the idea that lithium exerts its effect through GSK-3 inhibition. Levels of aggregated tau correlated strongly with degree of axonal degeneration, and lithium-chloride- treated mice showed less degeneration if administration was started during early stages of tangle development. These results support the idea that kinases are involved in tauopathy progression and that kinase inhibitors may be effective therapeutically.

KW - Alzheimer's disease

KW - Neurofibrillary tangles

KW - Phosphorylation

KW - Tau protein

UR - http://www.scopus.com/inward/record.url?scp=21044449225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044449225&partnerID=8YFLogxK

U2 - 10.1073/pnas.0500466102

DO - 10.1073/pnas.0500466102

M3 - Article

C2 - 15867159

AN - SCOPUS:21044449225

VL - 102

SP - 6990

EP - 6995

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 19

ER -